Results 101 to 110 of about 15,817 (194)

Entecavir [PDF]

Reactions Weekly, 2020
  +4 more sources

Prospects for Controlling Hepatitis B Globally

Pathogens
Infection with the hepatitis B virus (HBV) is highly prevalent globally. Over 250 million people suffer from chronic hepatitis B, and more than 800,000 patients die each year due to hepatitis B complications, including liver cancer.
Vicente Soriano, Víctor Moreno-Torres, Ana Treviño, Fernando de Jesús, Octavio Corral, Carmen de Mendoza   +5 more
doaj   +1 more source

Experience of entecavir in renal graft recipients with chronic hepatitis B

Российский журнал гастроэнтерологии, гепатологии, колопроктологии, 2011
Aim of investigation. To estimate efficacy and safety of entecavir (ETV) in chronic hepatitis B (CHB) at renal graft recipients (RGR).Material and methods.
M. L. Zubkin, Ye. P. Sel'kova, F. K. Kokoyeva, T. A. Semenenko, V. I. Chervinko, A. N. Kolomoyets, E. M. Balakirev, A. V. Frolov, T. P. Nekrasova   +8 more
doaj  

Serum miR-146a and miR-155 as Predictors of Virological Control After Entecavir Withdrawal in HBeAg-Positive Chronic Hepatitis B Patients

The Turkish Journal of Gastroenterology
Background/Aims: Distinct virological relapse (VR) has occurred after stopping the use of nucleos(t)ide analogues treatment in patients with chronic hepatitis B (CHB) who are positive for Hepatitis B e antigen (HBeAg).
Ming Li Xu, Li Huan Wang
doaj   +1 more source

Thrombocytopenia in end-stage renal disease and chronic viral hepatitis B or C [PDF]

, 2018
Objectives. We evaluated platelet counts in end-stage renal disease and chronic viral hepatitis. Materials and Methods. We studied 70 patients with end-stage renal disease and chronic viral hepatitis and compared them to a control group of 45 patients ...
Breaban, Iulia, Ciulei, George, Cozma, Angela, Negrean, Vasile, Orasan, Olga Hilda, Orasan, Remus Aurel, Patiu, Ioan Mihai, Sampelean, Dorel, Secara, Sorina Cezara, Sitar Taut, Adela, Stefan, Andreea Maria, Tarmure Sarlea, Simina, Urian, Laura   +12 more
core   +1 more source

Resultados a largo plazo del tratamiento de la hepatitis B crónica con análogos de nucleótidos/sidos. [PDF]

, 2018
[ES] El objetivo de este trabajo es establecer si los análogos de nucleótidos/nucleósidos de administración oral entecavir y tenofovir son eficaces y seguros en el tratamiento de la hepatitis B crónica, comparando los resultados de nuestro estudio con ...
Salmón Olavarría, Pablo
core  

Global progress on the elimination of viral hepatitis as a major public health threat: an analysis of WHO Member State responses 2017 [PDF]

, 2019
Blach, Day, Degenhardt, Global Reporting System for Hepatitis, Heffernan, Hill, Hutin, Hutin, Hutin, Nayagam, Razavi, WHO, World Health Organization, World Health Organization, World Health Organization, World Health Organization, World Health Organization, World Health Organization, World Health Organization, World Health Organization, World Health Organization, World Health Organization, World Hepatitis Alliance   +22 more
core   +1 more source

Is tenofovir and entecavir combination therapy still the optimal treatment for chronic hepatitis B patients with prior suboptimal response? [PDF]

Clinical and Molecular Hepatology, 2020
Byoung Kuk Jang
doaj   +1 more source

Evaluación de la costo-efectividad de entecavir versus lamivudina en pacientes con hepatitis B crónica

Acta Gastroenterológica Latinoamericana, 2008
La infección crónica por el virus de la hepatitis B representa una importante carga de enfermedad en el mundo y en Argentina. Existen nuevas estrategias terapéuticas, entre ellas el entecavir, un análogo nucleósido.
Juan Ignacio Calcagno, Federico Augustovski, Adrián Gadano, Alberto Souto, Yong Yuan   +4 more
doaj  

Intracranial hepatitis B virus (HBV) infection following intracerebral hemorrhage in a patient with seronegative occult HBV infection. [PDF]

IDCases
Ji X, Wang M, Jin P, Kong L, Xu Y, Chen W, Liu B, Wang Q.   +7 more
europepmc   +1 more source